Kornimate/medical-research-clean huggingface dataset:
effectiveness of educational intervention on footcare among individuals having type 2 diabetes at slums of karachi, pakistan.

Conditions: Diabetic Foot; Educational Intervention; Foot Care; Foot Ulcer, Diabetic; Foot Cellulitis

Summary: there are multiple studies conducted in pakistan that supports the topic of foot care knowledge among individual with type 2 diabetes but all are descriptive cross-sectional studies and investigators cannot develop cause effect relationship out of it. secondly, there is a lack of documented research on the foot care knowledge shown by people with t2d residing in the slums of karachi. in order to assess the knowledge intervention among the individual having t2d through qualified diabetes educators and pictorial educational pamphlet along with the standard care of treatment. consequently, it may aid in the development of effective methods aimed at mitigating foot-related complications among this specific population. individuals diagnosed with diabetes are required to engage in proactive and structured self-care activities by providing the foot care knowledge in order to effectively manage their condition and mitigate the risk of potential complications. the incorporation of health-deviation knowledge and activities into routine is crucial.


Eligibility criteria:
inclusion criteria: * 1. patients aged 18 years or older. * patients who are registered at designated sina clinic and clinical and biochemical diagnosis of dm for at least six months * patients who are able to understand urdu language will be included in the study * patients who are voluntarily participated the study will be included. exclusion criteria: * patients come with recurrent foot ulcers or gangrene. * history of amputation * patient live in other than designated slums location.

Keywords: type 2 diabetes slums population vulnerable population low-socioeconomic status diabetes foot care knowledge on foot care
safety, pharmacokinetic and pharmacodynamic study of cor-1, an anti-ß1 receptor antibody cyclopeptide

Conditions: Heart Failure

Summary: primary trial objectives: to evaluate the pharmacokinetics and -dynamics of five strengths of cor-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose level, 10 subjects receiving placebo) secondary objectives: to evaluate safety and tolerability by using adverse events (aes) and vital signs

primary trial objective: to evaluate the pharmacokinetics and -dynamics of five strengths of cor-1 (10, 40, 80, 160, 240 mg) in healthy, male volunteers after single intravenous administration secondary objectives: to evaluate safety and tolerability by using adverse events (aes), vital signs including blood pressure/pulse rate (bp/pr), electrocardiographic examinations (12 lead ecg), evaluation of antibody titer and safety laboratory tests (biochemistry, hematology, coagulation, urinalysis) methodology: mono-center, single-blind, dose escalating study with five dose levels (8 subjects on verum per dose level, 2 subjects receiving placebo) in a total of 50 volunteers.

Eligibility criteria:
inclusion criteria: * healthy, male caucasians between 18 and 45 years of age, inclusive * normotensive subjects (systolic bp \<140 mmhg and diastolic bp \<90 mmhg) * body mass index (bmi) 19-27, minimal weight 60 kg * negative results in hiv antibody, hbs antigen (hbsag) and hcv tests, and negative result in anti-ß1-receptor-autoantibody screening * signed informed consent form * normal or clinically irrelevant laboratory findings exclusion criteria: * autoimmune disorders * kidney diseases * liver diseases, liver function impairments

Keywords: anti-beta1 adrenergic receptor autoantibody cyclic peptide heart failure
optical coherence tomography angiography examinations in chronic retinal artery occlusion

Conditions: Retinal Artery Occlusion

Summary: purpose of the study is to examine the retinal blood flow in chronic cases of retinal artery occlusion with non-invasive, non-contact optical coherence tomography angiography.

occlusion of the retinal arteries is an emergency which causes sudden, painless unilateral vision loss. loss of blood flow causes ischemic damage to the retina. the extent of damage depends on the area affected. following the acute phase of the disease re-canalization occurs and lesser blood flow can be detected usually without functional recovery. purpose of the study is to examine the retinal blood flow in chronic cases of retinal artery occlusion. standard procedures to examine this disease include retinoscopy following pupil dilation, fluorescein angiography and more recently, optical coherence tomography (oct). the latest direction in oct development was oct angiography (octa) which is a software upgrade that allows detection of blood flow based on motion contrast. similar to previous oct machines octa is also non-invasive and non-contact and does not require any intravenous agents. oct machines are approved in the eu and the us and are not experimental devices. the device used in this study is the commercially available zeiss cirrus hd oct angioplex 5000 that operates with spectral-domain technology.

Eligibility criteria:
inclusion criteria: * central or branch retinal artery occlusion * at least 6 months of onset * signed informed consent exclusion criteria: * known epilepsy * incapacity * presence of optical media opacities that would disturb the imaging * presence of other retinal diseases that would disturb the evaluation of images
efficacy and safety of grass pollen sublingual immunotherapy

Conditions: Allergic Rhinoconjunctivitis

Summary: the study is assessing efficacy and safety of three different dosage regimens of grass pollen sublingual immunotherapy in adult patients suffering from grass pollen related rhinoconjunctivitis.

patients with seasonal grass pollen related rhinoconjunctivitis will be randomized to one of four treatment groups at 41 centres in europe. each treatment group will consist of approximately 150 patients and 150 patients will be randomized to a placebo group. the study will consist of a screening phase, a treatment phase and a variable maintenance period.

Eligibility criteria:
inclusion criteria: * male or female aged 18-50 * patients with grass pollen related allergic rhinoconjunctivitis for at least 2 pollen seasons * positive skin prick test and ige value of at least class 2+ * rtss of greater or equal to 14 during pollen season prior tot the start of the study * patients must be in general good health * patients with normal spirometry * informed consent given and willing to comply with the protocol * female patients are eligible if they use an accepted contraceptive method * negative urine pregnancy test if female exclusion criteria: * pregnancy, breast feeding * asthma requiring treatment other than beta-2 inhaled agonists * patients who have taken oral steroids within 12 weeks before screening visit * patients who have received desensitisation treatment for grass pollen * treatment by immunotherapy with any other allergen within the previous 5 years * patients who have suffered a lower respiratory tract infection within 4 weeks or an upper respiratory tract infection within 2 weeks of the screening visit * patients at risk of non-compliance * participation in any other clinical study within the previous 3 months * patients with a past or current disease, which may affect participation in or outcome of this study. * patients treated with beta-blockers or under continuous corticotherapy * allergic sensitivity to epithelial allergens the patients is exposed to * positive skin prick test for environmental allergens and suffering from serious allergic symptoms due to exposure to these allergens during study period * intention to subject the patient to surgery of the nasal cavity during current study * usual contraindications of immunotherapy * a clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to tree pollen or weed pollen adjacent to the start of, and potentially overlapping the grass pollen season

Keywords: randomised double-blind placebo-controlled efficacy and safety oralgen® grass pollen allergic rhinoconjunctivitis allergy rhinoconjunctivitis immunotherapy grass pollen extract
real-world registry - the vivally® system

Conditions: Urinary Incontinence; Urinary Urge Incontinence

Summary: this is a real-world registry study to collect real-world dosing, utilization, demographic, quality of life, and data from the e-bladder diaries of patients utilizing the vivally® system. data points will be drawn from the avation medical hipaa-compliant cloud database including but not limited to: therapy compliance and stimulation metrics diary entries provided by patients various questionnaires participants have the option to opt out of allowing their data to be part of any publication at any time.

collect real-world dosing, utilization, demographics and quality of life data from the ediaries of patients utilizing the vivally® system. gather feedback from patients on their experience and satisfaction with the vivally® system therapy identify trends in dosing, compliance, and therapy parameters in order to optimize the wearable, vivally® system neuromodulation therapy for participants

Eligibility criteria:
inclusion criteria: to be eligible for the real-world registry study, participants must satisfy all of the following criteria: * are an appropriate candidate for the vivally® system as determined, and prescribed by a licensed clinical professional * have provided informed consent to have their data included in publications associated with this study exclusion criteria: while it is up to the discretion of the clinician to prescribe the vivally® system for a specific patient, the vivally® system is contraindicated for use on patients who have the following history or conditions: * patients with pacemakers of implanted defibrillators * patients with nerve damage that could impact either transcutaneous tibial nerve stimulation or pelvic floor function * this product is not intended for intra-cardiac or trans-thoracic use additional contraindications, warnings and precautions are listed in the user guide.

Keywords: neuromodulation overactive bladder overactive bladder syndrome wearable non-invasive mobile application electronic bladder diary urgency
a novel patient decision aid for surrogate decision makers of comatose survivors of cardiac arrest

Conditions: Cardiac Arrest With Successful Resuscitation

Summary: this study will test the feasibility and acceptability of deploying a decision aid for surrogate decision makers of comatose survivors of cardiac arrest early during hospitalization. this decision aid is to inform, educate and support decision makers charged with determining goals of care during post-cardiac arrest treatment.

survival and neurological recovery after out-of-hospital cardiac arrest are highly variable, driven in part by inconsistent hospital care following successful resuscitation. international guidelines for post-cardiac arrest care recommend delaying neurologic prognostication until 72-hours after resuscitation because early prognostication is imprecise and may precipitate inappropriate withdrawal of life sustaining therapy (wlst). early wlst has been observed in-post cardiac arrest care. in order to encourage better guideline concordant care, the study proposes the implementation of an educational tool to support and inform surrogate decision makers in post-cardiac arrest care and neuro-prognostication. this pilot study will test the feasibility of implementing an educational tool for surrogate decision makers, the acceptability of such an intervention and early measures of knowledge translation. this study will inform the creation of a randomized controlled trial to test the ability of the tool to encourage guideline concordant timing of post-cardiac arrest neuro-prognostication.

Eligibility criteria:
inclusion criteria: * adult 18 years of age and older * identified as a surrogate decision maker for patient who is a comatose survivor of out of hospital cardiac arrest exclusion criteria: * illiterate or poor proficiency (unable to read decision aid) * non-english speaking

Keywords: neurologic prognosis guideline concordance surrogate decision makers
correlation between intestinal microflora metabolites and amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: to verify the correlation between tmao level and the pathogenesis and progression of als

amyotrophic lateral sclerosis (als) is a fatal neurodegenerative disease with rapid progression, poor prognosis and unknown etiology. at present, there is no effective treatment. in recent years, with the deepening of the research on the interaction between intestinal flora and human health, many studies have found that intestinal flora is closely related to neurodegenerative diseases. in the field of neuroscience, there are more and more researches on the relationship between tmao and its precursors (l-carnitine, etc.) and neurodegenerative diseases. although there is no direct study on the relationship between tmao and als, the relevant experiments suggest that intestinal flora, tmao and its precursors (l-carnitine, etc.) may be involved in the pathogenesis and progression of als. the purpose of this study is to verify the important role of tmao, a metabolite of intestinal flora, in als through human studies and animal model studies, and to obtain direct evidence that tmao participates in the disease process of als.

Eligibility criteria:
inclusion criteria: * ① als patients in outpatient or ward voluntarily participated in the study and signed informed consent by themselves or their authorized family members; ② at the time of enrollment, the diagnostic grade of als patients met the criteria of the world federation of neurology (wfn) revised in 1998; ③ they were 18-75 years old; ④ antibiotics, l-carnitine and intestinal flora regulation were not used within 3 months; ⑤ can eat normally. exclusion criteria: * ① electromyography detection found motor nerve block, sensory nerve conduction abnormalities, or imaging examination (ct or mri) found lesions that could explain the clinical manifestations of patients, which did not support the diagnosis of als; ② the patients with dementia or mental disorder could not cooperate with the researchers; ③ patients with severe heart, liver, kidney and other severe concomitant diseases; ④ patients with gastrointestinal diseases or gastrointestinal surgery may affect gastrointestinal absorption; ⑤ the patients who were treated with antibiotics, l-carnitine and intestinal flora regulation in recent 3 months; ⑥ breast feeding or pregnancy; ⑦ patients with dysphagia, inability to eat normal food, or indwelling gastric tube or gastrostomy for enteral nutrition.
a study to evaluate the efficacy and safety of nbi-1070770 in adults with major depressive disorder

Conditions: Major Depressive Disorder

Summary: to evaluate the efficacy, safety, and tolerability of nbi-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (mdd).


Eligibility criteria:
key inclusion criteria: participants must meet all of the following inclusion criteria: * primary diagnosis of recurrent mdd or persistent mdd. * participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s). * participants must be willing and able to comply with all study procedures and restrictions. key exclusion criteria: participants will be excluded from the study if they meet any of the following criteria: * participant is pregnant or breastfeeding or plan to become pregnant during the study. * participant has an unstable medical condition or unstable chronic disease. * participant has a history of neurological abnormalities. * participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than mdd. * participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy. * participant has an alcohol or substance use disorder. note: other inclusion/exclusion criteria may apply

Keywords: major depressive disorder mdd nbi-1070770 neurocrine antidepressant depression montgomery-åsberg depression rating scale madrs
evaluation of computerized template entry for compensation and pension (c&p) examinations

Conditions: Joint Diseases

Summary: the purpose of this study is to compare c\&p examination reports performed using a compensation and pension examination program (cpep) computerized, templated documentation tool to a customary examination performed and then report dictated in quality, completeness, timeliness and veteran satisfaction.


Eligibility criteria:
inclusion criteria: * subjects for the current study included veterans scheduled for c\&p examination of two or fewer joints at va tvhs. * no ethnic or racial group or gender was excluded. exclusion criteria: * veterans were excluded if they were scheduled: 1. for examination of more than two joints, 2. with other requested exam protocols in addition to joints

Keywords: disability evaluation joint diseases joint disability
liposomal bupivacaine (exparel) for postoperative pain control for open and laparoscopic abdominal hernia repair

Conditions: Pain

Summary: the purpose of this study is to learn how well liposomal bupivacaine (exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

when a person has surgery, there are a few different standard care options for pain relief. anesthetic (numbing) drugs can be used to cause a loss of feeling in or around a wound but the effect of the numbing medication can be undone.pain relieving drugs such as acetaminophen (tylenol), non-steroidal anti-inflammatory drugs (nsaids), and opioid (narcotic) medications can also be taken by mouth or through a vein in your arm (intravenous iv.) however, both nsaids \& opioid drugs can produce negative side effects such as serious difficulty breathing, stopping breathing altogether, low blood pressure, nausea, vomiting, itching, and constipation. bupivacaine is one of the commonly used longer-acting numbing medicines (anesthetics). the effect of bupivacaine or other anesthetics is limited to usually no more than 12 hours when injected around the area of the incision during surgery. liposomal bupivacaine (exparel) could provide good, continuous and longer pain relief than current therapies/treatments commonly used. this can possibly improve patient satisfaction and time to normal activities such as walking.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo an open or laparoscopic abdominal hernia repair. * ability to provide informed consent, adhere to study visit schedule, and complete all study assessments. exclusion criteria: * patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids or ketorolac. * patients who abuse alcohol or other drug substance. * patients who are on chronic opioid therapy (taken an opioid 5 of the last 7 days). * patients with severe hepatic impairment. * patients currently pregnant.

Keywords: pain management exparel abdominal hernia repair laparoscopic surgery
gi biorepository of tissue and bodily fluids

Conditions: Gastrointestinal Diseases

Summary: the purpose of this study is to establish the working protocols for a general biorepository with the specific aim of procuring tissues and bodily fluids from the human gastrointestinal tract from a diverse range of clinical patients at the uc davis medical center. the establishment of a gi-specific biorepository will support future translational endeavors within the uc davis campus by providing laboratories with readily available gi tissue and bodily fluid samples to test newly developed hypotheses with relative ease.

uc davis is currently lacking a general use biorepository for gi tissues and bodily fluids. as with any translational research study, the procurement of human tissue samples can be a difficult and time- consuming process. the establishment of this biorepository will help streamline gi biospecimen collection and centralize these samples in a conveniently located space to facilitate the implementation of future unspecified translational studies.

Eligibility criteria:
inclusion criteria: * all consenting adults aged 18 years or older with an appointment with a healthcare professional in the division of gastroenterology or the department of surgery exclusion criteria: * minors, pregnant women, prisoners, and all other vulnerable populations who are unable to consent.
trial of variable dialysate bicarbonate

Conditions: Peri-dialytic Cardiac Rhythms; Intradialytic Hypotension; Electrolyte Changes; pH Changes; Adverse Symptoms

Summary: qtc prolongation and premature ventricular contractions (pvcs) are common in hemodialysis (hd) patients and are associated with sudden cardiac death. it is known that higher dialysate bicarbonate is associated with more qtc prolongation during hd sessions. this study aims to assess the effects of lower (30 meq/l) versus higher (35 meq/l) dialysate bicarbonate in adult maintenance hd patients admitted to the hospital. the investigators will randomly assign subjects to lower versus higher dialysate bicarbonate concentrations during their hospital stay for up to a maximum of six hd sessions or until their hospital discharge.


Eligibility criteria:
inclusion criteria: * prevalent end-stage renal disease, on maintenance hd \> 90 days * age ≥ 18 years old * thrice weekly hd exclusion criteria: * hemoglobin \< 8.0 g/dl * pregnancy * any physical, mental or medical condition which limited the ability to provide written informed consent
effects of flywheel resistance training on cognitive function in stroke patients

Conditions: Stroke

Summary: forty patients will be assigned to either a training group (12 wk unilateral knee extension flywheel resistance exercise; 4 sets of 7 reps 2 days/week) or a control group. patients will maintain daily routines and any prescribed rehabilitation program. established methods to assess muscle and cognitive function will be employed before and after the intervention. this project will disclose whether an exercise paradigm, known to improve muscle function and increase muscle volume in healthy populations, will induce similar adaptations in chronic stroke patients. more importantly, this study will elucidate if any impairment in cognitive function caused by stroke, can be reversed with this particular resistance exercise regimen. the information gained from this project will have significant implications and aid in advancing rehabilitation programs and exercise prescriptions for men and women suffering from stroke. the overall objective of this research is to promote independence and hence quality of life in these patients.


Eligibility criteria:
inclusion criteria: * mild-moderate hemiparetic gait * \> 6 months post-stroke * able to perform flywheel leg-press exercise exclusion criteria: * unstable angina * congestive heart failure * severe arterial disease * major depression * dementia * chronic pain * psychotic alterations

Keywords: stroke flywheel resistance exercise muscle function cognitive function